The effects of fluconazole and cytokines on human mononuclear cells

Memorias do Instituto Oswaldo Cruz

Volumn 102, Issue 2, 2007, Pages 127-131

  Fidan, Isil ^a   Yuksel, Sevgi ^a   Imir, Turgut ^a   Kalkanci, Ayse ^a   Kustimur, Semra ^a   Ilhan, Mustafa N ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Candida albicans; Chemokines; Cytokines; Fluconazole

Indexed keywords

CANDIDA; CANDIDA ALBICANS;

EID: 34047230492     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762007005000021     Document Type: Article

References (20)

1. Anaissie EJ, McGinnis MR, Pfaller MA 2003. The epidemiology of fungal infection. In Clinical Mycology, Churchill Livingstone, New York, p.1-19.
2. Armstrong R 2001. The physiological role and pharmacological potential of nitric oxide in neutrophil activation. Int Immunopharmacol 1: 1501-1512.
3. Ashman RB, Farah CS, Wanasaengsakul S, Hu Y, Pang G, Clancy RL 2004. Innate versus adaptive immunity in Candida albicans infection. Immunol Cell Biol 82: 196-204.
4. Baltch AL, Bopp LH, Smith RP, Ritz WJ, Carlyn CJ, Michelsen PB 2005. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon γ on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diag Microb Infect Dis 52: 299-304.
5. Baltch AL, Smith RP, Franke MA, Ritz WJ, Michelsen PB, Bopp LH 2001. Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob Agents Chemother 45: 96-104.
6. Bodasing N, Seaton RA, Shankland GS, Pithie A 2002. Gammainterferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 50: 765-766.
7. Farmaki E, Roilides E 2001. Immunotherapy in patients with systemic mycoses: a promising adjunct. Bio Drugs 15: 207-214.
8. Huang C, Levitz SM 2000. Stimulation of Macrophage inflammatory protein-1α, macrophage inflammatory protein-1β, and RANTES by Candida albicans and Cryptococcus neoformans in peripheral blood mononuclear cells from persons with and without human immunodeficiency virus infection. J Infect Dis 181: 791-794.
9. Louie A, Baltch AL, Smith RP, Franke MA, Ritz WJ, Singh JK, Gordon MA 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun 62: 2761-2772.
10. Maertens JA 2004. History of the development of azole derivatives. Clin Microbiol Infect 10 (Suppl. I): 1-10.
11. Marodi L, Schreiber S, Anderson DC, MacDermott RP, Korchak HM, Johnston RB 1993. Enhancement of macrophage candidacidal activity by interferon-γ. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 91: 2596-2601.
12. Mencacci A, Cenci E, Bacci A, Bistoni F, Romani L 2000. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J Infect Dis 181: 686-694.
13. NCCLS 2002. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, 2nd ed., p. 1-29, Wayne, Pennsylvania.
14. Saavedra M, Taylor B, Lukacs N, Fidel PL 1999. Local production of chemokines during experimental vaginal candidiasis. Infect Immun 67: 5820-5826.
15. Sheehan DJ, Hitchcock CA, Sibley CM 1999. Current and emerging azole antifungal agents. Clin Microbiol Rev 12: 40-79.
16. Simitsopoulou M, Roilides E, Dotis J, Dalakiouridou M, Dudkova F, Andreadou E, Walsh TJ 2005. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 49: 1397-1403.
17. Steele C, Fidel PL 2002. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immun 70: 577-583.
18. Vazquez JA, Hidalgo JA, De Bono S 2000. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 1: 23-29.
19. Vora S, Purimetla N, Brummer E, Stevens DA 1998. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 42: 907-910.
20. Yamamoto Y, Klein TW, Tomioka M, Friedman H 1997. Differential effects of granulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage resistance to Legionella pneumophila vs Candida albicans. Cell Immunol 176: 75-81.